181 related articles for article (PubMed ID: 34821198)
1.
Mohapatra PK; Chopdar KS; Dash GC; Mohanty AK; Raval MK
J Biomol Struct Dyn; 2023 Feb; 41(2):435-444. PubMed ID: 34821198
[TBL] [Abstract][Full Text] [Related]
2. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
[TBL] [Abstract][Full Text] [Related]
3.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
4. Molecular insights to the binding interactions of APNS containing HIV-protease inhibitors against SARS-CoV-2 M
Purohit P; Dash JJ; Muya JT; Meher BR
J Biomol Struct Dyn; 2023 Jun; 41(9):3900-3913. PubMed ID: 35388744
[TBL] [Abstract][Full Text] [Related]
5. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease.
Wang Y; Gao Q; Yao P; Yao Q; Zhang J
J Biomol Struct Dyn; 2023; 41(24):15262-15285. PubMed ID: 36961210
[TBL] [Abstract][Full Text] [Related]
6. Fourteen immunomodulatory alkaloids and two prenylated phenylpropanoids with dual therapeutic approach for COVID-19: molecular docking and dynamics studies.
Omar R; Abd El-Salam M; Elsbaey M; Hassan M
J Biomol Struct Dyn; 2024 Mar; 42(5):2298-2315. PubMed ID: 37116054
[TBL] [Abstract][Full Text] [Related]
7. Identification of natural inhibitors against Mpro of SARS-CoV-2 by molecular docking, molecular dynamics simulation, and MM/PBSA methods.
Sharma P; Joshi T; Mathpal S; Joshi T; Pundir H; Chandra S; Tamta S
J Biomol Struct Dyn; 2022 Apr; 40(6):2757-2768. PubMed ID: 33143552
[TBL] [Abstract][Full Text] [Related]
8. Virtual Screening of
Miandad K; Ullah A; Bashir K; Khan S; Abideen SA; Shaker B; Alharbi M; Alshammari A; Ali M; Haleem A; Ahmad S
Molecules; 2022 Nov; 27(22):. PubMed ID: 36432204
[TBL] [Abstract][Full Text] [Related]
9. Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum.
Gyebi GA; Elfiky AA; Ogunyemi OM; Ibrahim IM; Adegunloye AP; Adebayo JO; Olaiya CO; Ocheje JO; Fabusiwa MM
Comput Biol Med; 2021 Sep; 136():104671. PubMed ID: 34332348
[TBL] [Abstract][Full Text] [Related]
10.
Chandel V; Tripathi G; Nayar SA; Rathi B; Kumar A; Kumar D
J Biomol Struct Dyn; 2022; 40(19):8850-8865. PubMed ID: 33939590
[TBL] [Abstract][Full Text] [Related]
11. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation.
Kar P; Kumar V; Vellingiri B; Sen A; Jaishee N; Anandraj A; Malhotra H; Bhattacharyya S; Mukhopadhyay S; Kinoshita M; Govindasamy V; Roy A; Naidoo D; Subramaniam MD
J Biomol Struct Dyn; 2022 Jul; 40(10):4532-4542. PubMed ID: 33305988
[TBL] [Abstract][Full Text] [Related]
12. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
Ancy I; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of multiple SARS-CoV-2 proteins by an antiviral biomolecule, seselin from
Nivetha R; Bhuvaragavan S; Muthu Kumar T; Ramanathan K; Janarthanan S
J Biomol Struct Dyn; 2022; 40(21):11070-11081. PubMed ID: 34431451
[TBL] [Abstract][Full Text] [Related]
14. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target.
Kundu D; Selvaraj C; Singh SK; Dubey VK
J Biomol Struct Dyn; 2021 Jun; 39(9):3428-3434. PubMed ID: 32362243
[TBL] [Abstract][Full Text] [Related]
15. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
Abdizadeh R; Hadizadeh F; Abdizadeh T
Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
[TBL] [Abstract][Full Text] [Related]
16. In-Silico approach for identification of effective and stable inhibitors for COVID-19 main protease (M
Das P; Majumder R; Mandal M; Basak P
J Biomol Struct Dyn; 2021 Oct; 39(16):6265-6280. PubMed ID: 32705952
[TBL] [Abstract][Full Text] [Related]
17. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.
Kumar D; Kumari K; Vishvakarma VK; Jayaraj A; Kumar D; Ramappa VK; Patel R; Kumar V; Dass SK; Chandra R; Singh P
J Biomol Struct Dyn; 2021 Aug; 39(13):4671-4685. PubMed ID: 32567995
[TBL] [Abstract][Full Text] [Related]
18.
Rajendran M; Roy S; Ravichandran K; Mishra B; Gupta DK; Nagarajan S; Arul Selvaraj RC; Provaznik I
J Biomol Struct Dyn; 2022 Apr; 40(7):3155-3169. PubMed ID: 33200680
[TBL] [Abstract][Full Text] [Related]
19. MD simulation and MM/PBSA identifies phytochemicals as bifunctional inhibitors of SARS-CoV-2.
Sharma M; Mahto JK; Dhaka P; Neetu N; Tomar S; Kumar P
J Biomol Struct Dyn; 2022; 40(22):12048-12061. PubMed ID: 34448684
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL
Alamri MA; Tahir Ul Qamar M; Mirza MU; Bhadane R; Alqahtani SM; Muneer I; Froeyen M; Salo-Ahen OMH
J Biomol Struct Dyn; 2021 Aug; 39(13):4936-4948. PubMed ID: 32579061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
